1. Home
  2. PEB vs URGN Comparison

PEB vs URGN Comparison

Compare PEB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pebblebrook Hotel Trust of Beneficial Interest

PEB

Pebblebrook Hotel Trust of Beneficial Interest

HOLD

Current Price

$11.26

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$21.79

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEB
URGN
Founded
2009
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2009
2017

Fundamental Metrics

Financial Performance
Metric
PEB
URGN
Price
$11.26
$21.79
Analyst Decision
Hold
Strong Buy
Analyst Count
9
8
Target Price
$12.28
$28.50
AVG Volume (30 Days)
2.0M
998.4K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
0.35%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,464,126,000.00
$96,516,000.00
Revenue This Year
$2.32
$27.96
Revenue Next Year
$2.42
$123.02
P/E Ratio
N/A
N/A
Revenue Growth
0.99
8.00
52 Week Low
$7.42
$3.42
52 Week High
$14.85
$30.00

Technical Indicators

Market Signals
Indicator
PEB
URGN
Relative Strength Index (RSI) 56.64 42.19
Support Level $10.67 $21.74
Resistance Level $11.71 $30.00
Average True Range (ATR) 0.34 1.56
MACD 0.02 -0.72
Stochastic Oscillator 61.24 3.15

Price Performance

Historical Comparison
PEB
URGN

About PEB Pebblebrook Hotel Trust of Beneficial Interest

Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: